Abstract:Wei-Ying Diao, 1, &ast Cheng-Long Ding, 1, &ast Bo-Yang Yuan, 2 Zan Li, 3 Na Sun, 4 Jia-Bin Huang 5 1 Department of Pathology, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China; 2 Department of Acupuncture and Moxibustion, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China; 3 Department of Analytical Chemistry Teaching and Research, Jiamusi University, Jiamusi City, Heilongjiang Province, 154002, People's Republic of China; 4 Graduate Department, Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China; 5 Department of Geratology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jia-Bin Huang Email Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients. Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared. Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes ( P 0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients ( P < 0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group ( P < 0.05). Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB∼IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients. Keywords: non-small cell lung cancer, HER2 genotype, CT signs, afatinib As one of the most prevalent malignant tumors worldwide, lung cancer has become the top cause of cancer-related death in the urban population of China. Non-small cell lung cancer (NSCLC) includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, in which cancer cells grow and divide more slowly, and spread and metastasize are less drastic. 1,2 NSCLC accounts for about 80% of overall lung cancers, and approximately 75% of patients have progressed in the advanced stage when diagnosed, with somber 5-year survival rate. 3 At present, the treatment of NSCLC mainly includes surgery, radiotherapy, chemotherapy, immunotherapy, etc. A large number of studies have shown that the occurrence and development of lung cancer are consequent to the unbalanced regulation of multiple gene expression, which is closely related to the stability of genes in organisms. 4,5 Human Epithelial Factor Receptor-2 (HER2) is a member of the epithelial factor receptor family. Studies demonstrated that HER2 overexpression is an enhancer of EGFR signaling, and it plays a role in signal transduction in cancer development and progress when HER2 is dysfunctional. 6 Afatinib and trezizumab have been recommended as targeted therapies for patients with HER2 mutation -Abstract Truncated-

Clinicopathological Analysis of Large Cell Lung Carcinomas Definitely Diagnosed According to the New World Health Organization Criteria.

[Large-Cell Lung Carcinoma by the 2015 WHO Classification: a Clinicopathologic Analysis of 93 Cases].

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Lymph node metastasis in Chinese patients with clinical T1 non-small cell lung cancer: A multicenter real-world observational study.

Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis

Clinical characteristics and gene mutation analysis of clear cell tumor of the lung

Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database.

Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study

Clinical Features And Outcomes Analysis Of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

Comparative Study of Large Cell Neuroendocrine Carcinoma and Small Cell Lung Carcinoma in High-Grade Neuroendocrine Tumors of the Lung: a Large Population-Based Study

Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR Mutations.

Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease

Correlation of Genes Associated with Drug Response to Prognosis of Large Cell Lung Carcinoma.

Comparative Study of the Genomic Landscape and Tumor Microenvironment among Large Cell Carcinoma of the Lung, Large Cell Neuroendocrine of the Lung, and Small Cell Lung Cancer

Clinical features and treatment outcomes of resected large cell neuroendocrine carcinoma of the lung

The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung

Changing profile of lung cancer clinical characteristics in China: Over 8-year population-based study

Clinicopathological characteristics and cancer-specific prognosis of primary pulmonary lymphoepithelioma-like carcinoma: a population study of the US SEER database and a Chinese hospital

Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer